demonstrated that the PI3K/Akt/mTOR pathway is constitutively active in primary AML blasts and is required for their survival while normal HSCs don’t rely on mTOR for long- or short-term survival (51). This evidence concerns the gene AKT1 and acute myeloid leukemia.